Two abstracts presented at the American Thoracic Society 2024 International Conference analyzed the phase 3 LIBERTY COPD BOREAS trial, finding that dupilumab improves pre- and post-bronchodilator lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback